Basilea Pharmaceutica AG
OTC: BPMUF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- David Veitch
- Employees
- 164
- Headquarters
- Allschwil, Switzerland
- IPO year
- 2015
- Market cap
- $746.0M
- Website
- https://www.basilea.com
Loading BPMUF…
Loading profile data…Frequently asked questions about BPMUF
What does Basilea Pharmaceutica AG (BPMUF) do?
Basilea Pharmaceutica AG is a biopharmaceutical company already generating revenue from its products, which are designed to fulfill medical needs in the challenging areas of cancer (oncology) and infectious diseases (anti-infectives). The company's product portfolio includes Cresemba, an azole antifungal drug administered intravenously or orally...
Where does BPMUF trade?
Basilea Pharmaceutica AG (BPMUF) trades on the Other OTC.
What sector is BPMUF in?
Basilea Pharmaceutica AG (BPMUF) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Basilea Pharmaceutica AG?
David Veitch is the chief executive officer of Basilea Pharmaceutica AG (BPMUF).
Where is Basilea Pharmaceutica AG headquartered?
Basilea Pharmaceutica AG is headquartered in Switzerland.
Does BPMUF pay a dividend?
Basilea Pharmaceutica AG (BPMUF) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did BPMUF go public?
Basilea Pharmaceutica AG (BPMUF) completed its initial public offering in 2015.